A Phase 3, Randomized, Open-label, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543/IMG-7289) Versus Best Available Therapy (BAT) in Participants With Essential Thrombocythemia Who Have an Inadequate Response to or Are Intolerant of Hydroxyurea

Summary

This is a study evaluating the safety and efficacy of bomedemstat (MK-3543) compared with the best available therapy (BAT) in participants with essential thrombocythemia (ET) who have an inadequate response to or are intolerant of hydroxyurea. The primary study hypothesis is that bomedemstat is superior to the best available therapy with respect to durable clinicohematologic response (DCHR).

Eligibility

Age range

18+ years

Sex

All

Healthy volunteers

No

Interventions

• Drug
  Bomedemstat

  Oral Capsule

• Drug
  Anagrelide

  Oral Capsule

• Drug
  Busulfan

  Oral Tablet

• Drug
  Interferon alfa/pegylated interferon alfa 2a/pegylated interferon alfa 2b

  Subcutaneous Solution

• Drug
  Ruxolitinib

  Oral Tablet

Locations (163)